EcoDrugPlus

Folate Receptor Alpha

Ensembl ID : ENSXETG00000044118
Gene Symbol: FOLR1
18 Enzyme and pathways 5 View Cross-references
436 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Follicle-Stimulating Hormone Receptor-Like

Ensembl ID : ENSXETG00000025827
Gene Symbol: LOC108647650
7 Enzyme and pathways 4 View Cross-references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Free Fatty Acid Receptor 2

Ensembl ID : ENSXETG00000042461
Gene Symbol: FFAR2
7 Enzyme and pathways 5 View Cross-references
356 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSXETG00000006166
Gene Symbol: FRK
5 View Cross-references
216 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Galactosidase Alpha

Ensembl ID : ENSXETG00000018146
Gene Symbol: GLA
7 Enzyme and pathways 5 View Cross-references
196 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid (Gaba) A Receptor, Alpha 1

Ensembl ID : ENSXETG00000031147
Gene Symbol: GABRA1
4 Enzyme and pathways 5 View Cross-references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid (Gaba) A Receptor, Alpha 2

Ensembl ID : ENSXETG00000008421
Gene Symbol: GABRA2
4 Enzyme and pathways 5 View Cross-references
255 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid (Gaba) A Receptor, Alpha 3

Ensembl ID : ENSXETG00000026177
Gene Symbol: GABRA3
4 Enzyme and pathways 5 View Cross-references
198 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid (Gaba) A Receptor, Alpha 5

Ensembl ID : ENSXETG00000027302
Gene Symbol: GABRA5
4 Enzyme and pathways 5 View Cross-references
266 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid (Gaba) A Receptor, Alpha 6

Ensembl ID : ENSXETG00000010239
Gene Symbol: GABRA6
4 Enzyme and pathways 5 View Cross-references
195 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid (Gaba) A Receptor, Beta 2

Ensembl ID : ENSXETG00000011917
Gene Symbol: GABRB2
4 Enzyme and pathways 5 View Cross-references
275 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid (Gaba) A Receptor, Beta 3

Ensembl ID : ENSXETG00000024288
Gene Symbol: GABRB3
4 Enzyme and pathways 5 View Cross-references
263 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).